{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}],"title":"complete response"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}],"title":"very good partial response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}],"title":"partial response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}],"title":"progressive disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"Find the response rate of the combination of melphalan, bendamustine, and carfilzomib as a conditioning regimen in patients with multiple myeloma undergoing autologous transplantation.","groups":[{"description":"Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 1: Carfilzomib 15 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6","id":"OG000","title":"Cohort 1: Carfilzomib 15 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 2: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6","id":"OG001","title":"Cohort 2: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 2b: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5","id":"OG002","title":"Cohort 2b: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 3b: Carfilzomib 27 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5","id":"OG003","title":"Cohort 3: Carfilzomib 27mgm2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Disease assessment at day +100, +180, and +365 (+/- 7 days).","title":"Response Rate","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}